Document Detail


Histone deacetylase inhibitors in oral squamous cell carcinoma treatment.
MedLine Citation:
PMID:  25216628     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Introduction: The involvement of the histone deacetylases (HDACs) family in tumor development and progression is well demonstrated. HDAC inhibitors (HDACis) constitute a novel, heterogeneous family of highly selective anticancer agents that inhibit HDACs and present significant antitumor activity in several human malignancies, including oral squamous cell carcinoma (OSCC). Areas covered: This review summarizes the current research on the anticancer activity of HDACis against OSCC. The review also presents the molecular mechanisms of HDACis action and the existing studies evaluating their utilization in combined therapies of OSCC. Expert opinion: The currently available data support evidence that HDACis may provide new therapeutic options against OSCC, decreasing treatment side effects and allowing a more conservative therapeutic approach. Future research should be focused on in vivo and clinical evaluation of their utilization as combined therapies or monotherapies. Before HDACis can be brought into clinical practice as treatment options for OSCC, further evaluation is needed to determine their optimal dosage, the appropriate duration of treatment and whether they should be used in combination or as stand-alone therapeutics.
Authors:
Jason Tasoulas; Constantinos Giaginis; Efstratios Patsouris; Evangelos Manolis; Stamatios Theocharis
Related Documents :
25342348 - Involving the public in research.
8185528 - A new tonometer prism stand.
25305148 - Participation in and support of clinical studies and other scientific investigations - ...
22704968 - Synthetic biology - the state of play.
18705168 - Identifying and responding to ethical and methodological issues in after-death intervie...
21814798 - Biobanking residual tissues.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-9-12
Journal Detail:
Title:  Expert opinion on investigational drugs     Volume:  -     ISSN:  1744-7658     ISO Abbreviation:  Expert Opin Investig Drugs     Publication Date:  2014 Sep 
Date Detail:
Created Date:  2014-9-13     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9434197     Medline TA:  Expert Opin Investig Drugs     Country:  -    
Other Details:
Languages:  ENG     Pagination:  1-10     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effect of manganese supplementation on the membrane integrity and the mitochondrial potential of the...
Next Document:  Pediatric cerebral ganglioneuroblastoma.